Um 18 Uhr geht's los: Jahresendrally - auf welche Aktien sollten Sie setzen? Jetzt kostenlos anmelden!
21.09.2021 15:20

Cannabics Pharmaceuticals hires Healthcare Investment Banker Dr. David Sans in New York to expand CNBX in Mental Health Diseases

Folgen
Werbung

TEL AVIV, Israel and BETHESDA, Maryland, Sept. 21, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today the hire of Dr. David Sans FAARM, PhD, MBA in New York to expand its current pipeline of clinical development assets in Mental Health Diseases. This announcement comes following the company's commitment to expand the current drug development programs with second generation of synthetic psychedelic inspired drugs.

Cannabics_Pharmaceuticals_Logo

Gabriel Yariv, company Executive Chairman said: "Psychedelic compounds have an increasing favorable regulatory environment and a growing body of clinical trials data demonstrating a remarkable degree of efficacy in difficult to treat mental health conditions. It is for these reasons that we are interested in this area, for helping patients with difficulties in treating their Mental Health Diseases and having a positive impact by expanding our current pipeline of synthetic compounds and investing in well-positioned, second-generation, synthetic psychedelic inspired medicine."

Eyal Barad, Cannabics Pharmaceuticals' Co-founder and CEO commented: "Dr. David Sans is a Healthcare Investment Banker in New York with over 12 years of banking experience and a wealth of knowledge in the CNS industry. David has led a number of transactions that are very relevant to Cannabics Pharmaceuticals and we welcome the opportunity to working with him."

About Cannabics Pharmaceuticals:

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) is a U.S. public company and a global leader in the development of cancer related cannabinoid-based medicine. The Company's R&D is based in Israel, where it is licensed by the Ministry of Health to conduct scientific and clinical research on cannabinoid formulations and cancer. For more information, please visit www.cannabics.com. For the latest updates on Cannabics Pharmaceuticals follow the Company on Twitter @Cannabics, Facebook @CannabicsPharmaceuticals, LinkedIn, and on Instagram @Cannabics_Pharmaceuticals.

Read more:

Recent expansion of Cannabics Pharmaceuticals' Board of Advisors to include: Prof. Caroline Robert (MD, Ph.D.), a Melanoma expert, and, Dr. Sigal Tavor (MD), a Hematology expertalong with Prof. Amos Toren (MD), Prof. Zamir Halpern (MD), Prof. Noam Shomron (Ph.D.), Dr. Erez Scapa (MD), Dr. Dana Ben-Ami Shor (MD), Dr. Sigalit Arieli-Portnoy (Ph.D.) and Dr. Tal Mofkadi (Ph.D.).

Recent expansion of Cannabics Pharmaceuticals' Board of Directors to include: Dr. Inbar Maymon-Pomeranchik (Ph.D.), and Dr. Gil Feiler (Ph.D.) as Independent Directors.

Disclaimer:

Certain statements contained in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. Such statements include but are not limited to statements identified by words such as "believes," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects" and similar expressions. The statements in this release are based upon the current beliefs and expectations of our Company's management and are subject to significant risks and uncertainties. Actual results may differ from those outlined in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission including, without limitation, our latest 10-Q Report filed July 14th, 2021. We undertake no duty to update any forward-looking statement or any information contained in this press release or other public disclosures at any time. Finally, the investing public is reminded that the only announcements or information about Cannabics Pharmaceuticals Inc., which are condoned by the Company, must emanate from the Company itself and bear our name as its source.

For more information about Cannabics:
Cannabics Pharmaceuticals Inc.
Phone: +1 (877) 424-2429
info@cannabics.com
http://www.cannabics.com

Related Links
https://www.cannabics.com

Cision View original content:https://www.prnewswire.com/news-releases/cannabics-pharmaceuticals-hires-healthcare-investment-banker-dr-david-sans-in-new-york-to-expand-cnbx-in-mental-health-diseases-301381508.html

SOURCE Cannabics Pharmaceuticals Inc.

Nachrichten zu Cannabics Pharmaceuticals

  • Relevant
  • Alle
  • vom Unternehmen
  • Peer Group
  • ?

Keine Nachrichten im Zeitraum eines Jahres in dieser Kategorie verfügbar.

Eventuell finden Sie Nachrichten, die älter als ein Jahr sind, im Archiv

Um Ihnen die Übersicht über die große Anzahl an Nachrichten, die jeden Tag für ein Unternehmen erscheinen, etwas zu erleichtern, haben wir den Nachrichtenfeed in folgende Kategorien aufgeteilt:

Relevant: Nachrichten von ausgesuchten Quellen, die sich im Speziellen mit diesem Unternehmen befassen

Alle: Alle Nachrichten, die dieses Unternehmen betreffen. Z.B. auch Marktberichte die außerdem auch andere Unternehmen betreffen

vom Unternehmen: Nachrichten und Adhoc-Meldungen, die vom Unternehmen selbst veröffentlicht werden

Peer Group: Nachrichten von Unternehmen, die zur Peer Group gehören

Analysen zu Cannabics Pharmaceuticals

  • Alle
  • Buy
  • Hold
  • Sell
  • ?
Keine Analysen gefunden.
mehr Analysen

Um 18 Uhr live: Jahresendrally - auf welche Aktien sollten Sie setzen?

Trotz eines vergleichsweise schwachen Marktes rechnen Experten mit einer intensiven Jahresendrally. Die Frage aller Fragen ist nun: Wer sind die Favoriten für 2022? Im Onine-Seminar heute ab 18 Uhr geben Ihnen Jürgen Schmitt und Mick Knauff einen exklusiven Ausblick.
Jetzt noch kostenlos anmelden!
Werbung

Meistgelesene Cannabics Pharmaceuticals News

Keine Nachrichten gefunden.
Weitere Cannabics Pharmaceuticals News
Werbung
Werbung
Werbung
Börse Stuttgart Anlegerclub
Werbung

Cannabics Pharmaceuticals Peer Group News

Keine Nachrichten gefunden.

Heute im Fokus

DAX leicht im Plus -- SEC entlastet GameStop-Shortseller -- Software AG senkt Ausblick für Digital -- Delivery Hero steigt bei Gorillas ein -- Apple, Evergrande, TeamViewer im Fokus

Ericsson enttäuscht mit weniger Umsatz - Operativer Gewinn überrascht positiv. Danone kann Drittquartalsumsatz steigern und bestätigt Jahresprognose. USA überarbeiten Sanktionspolitik - Risiko durch Bitcoin & Co. Apple will mit neuen M1-Chips PC-Markt aufrollen. Iberdrola baut für mehrere Milliarden Pfund drei Offshore-Windparks. BHP fördert im ersten Quartal weniger Eisenerz und Kupfer.

Umfrage

Wo steht der DAX zum Jahresende?

finanzen.net zero
finanzen.net zero

Oskar

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln